Merck Sharp + Dohme Corp.

Schering Corporation

Polaroid Corporation

Iomet Pharma Ltd.

Yongqi Deng

Gerald Wayne Shipps, Jr

Abdelghani Achab

Alan B Cooper

Hua Zhou

Yongxin Han

M Arshad Siddiqui

Hongjun Zhang

Kun Liu

Xiaolei Gao

Joseph Michael Kelly

Derun Li

Nunzio Sciammetta

Neng-Yang Shih

Wensheng Yu

Vincent Stewart Madison

David L Sloman

Jason David Katz

Alan W Hruza

Ronald J Doll

Joseph A Kozlowski

Neville J Anthony

Michael D Altman

Shuwen He

Joey Lee Methot

Liangqin Guo

Solomon D Kattar

Sunil Paliwal

Purakkattle J Biju

Rong Zhang

Li Xiao

Stephen J Telfer

James Han Wang

John L Marshall

Russell A Gaudiana

Timothy J Guzi

William T Vetterling

Janeta Popovici-Muller

Kevin J Wilson

Alain Bouchard

Phieng Siliphaivanh

Guoqing Li

Zhi-Cai Shi

David Joseph Guerin

Michael J Arnost

Umar Faruk Mansoor

Michael S Viola

Tong Wang

Xavier Fradera

Liang Zhu

Meredeth Ann McGowan

Hugh Y Zhu

Lianyun Zhao

Binyuan Sun

Qinglin Pu

Jagdish A Desai

Sobhana Babu Boga

James J-s Wang

Craig R Gibeau

Patrick J Curran

Hongbo Zeng

Hon-Chung Tsui

Catherine M White

Matthew Christopher

Rumin Zhang

Kin Chiu Fong

Zhaoyang Meng

Robert Sun

William T Windsor

Ahmed Abdi Samatar

Mehul F Patel

Francesc Xavier Fradera Llinas

Xiaohua Huang

Changwei Mu

Thierry Olivier Fischmann

Christopher Francis Thompson

Norman Kong

Feng Shi

Mark E Scott

Matthew H Daniels

Matthew Lloyd Childers

Christian Fischer

Peter H Fuller

Jayaram R Tagat

Andrew J McRiner

Kristin E Rosner

David Jonathan Bennett

Fariza B Hasan

Jose S Duca

Corey E Bienstock

Luis E Torres

Alan Wise

Liping Yang

Iwona Wrona

Michelle Martinez

Danielle Falcone

Gerald W Shipps

Indu T Bharathan

Brendan O'Boyle

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof:  Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Compounds as indoleamine 2,3-dioxygenase inhibitors

The instant invention provides compounds of Formula (I) which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors

The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer. 

Purine inhibitors of human phosphatidylinositol 3-kinase delta

The present invention provides a compound of the Formula I, or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R, R, R, R, m and are as defined herein. The compounds are ERK inhibitors. Also disclosed are pharmaceutical compositions that comprise the above compounds, and methods of treating cancer using the same. 

Indazole derivatives useful as ERK inhibitors

Disclosed are the ERK inhibitors of Formula (I): (Formula (I)) and the pharmaceutically acceptable salts thereof. All substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of Formula (I). 

Fused pyrazole derivatives as novel ERK inhibitors

Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof, wherein: A is a five membered monocyclic heteroaryl ring; and B is a monocyclic heterocycloalkyl ring, or a monocyclic heterocycloalkenyl ring, or a bridged monocyclic heterocycloalkyl ring, or a fused (monocyclic heterocycloalkyl ring) cyclopropyl ring. Also disclosed are methods of treating cancer using the compounds of formula (1). 

Compounds that are ERK inhibitors

The present invention provides a compound of the Formula I: (Formular I should be inserted here) or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R, R1, R2 and R3 are as defined herein. The compounds are ERK inhibitors. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same. 

Heterocyclic compounds as ERK inhibitors

Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, and solvates thereof. Q is a tetrahydropyridinyl ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0. 

The present invention provides Fused Tricyclic Compounds of the Formula (I) wherein Q, R, R, R, and Rare as defined herein, and pharmaceutically acceptable salts of such Fused Tricyclic Compounds. The Fused Tricyclic Compounds are useful in the treatment of cancer and other proliferative disorders. 

Fused Tricyclic Compounds as novel mTOR inhibitors

Growing community of inventors

Newton, MA, United States of America

Yongqi Deng